|
|
|
|
|
Alemtuzumab
drug data and news
Alemtuzumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Alemtuzumab | ||
| Brand Names/Synonyms | Campath; Campath (ILEX Pharmaceuticals LP) | ||
| Indication | For treatment of B-cell chronic lymphocytic leukemia | ||
| Sponsored links | Description | Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. | |
| Pharmacology | Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. | ||
| Mechanism Of Action | Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. | ||
| Alemtuzumab News (When available) |
Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006 Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antineoplastic Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | Humanized anti-CD52 antibody | ||
| Chemical Formula | C6468H10066N1732O2005S40 >1CE1:L CAMPATH-1H:Light Chain 1 >1CE1:H CAMPATH-1H:Heavy Chain 2 >1CE1:L CAMPATH-1H:Light Chain 2 | ||
| Molecular Weight | 145453.8 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) – Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.431 | ||
| Isoelectric Point | 8.76 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes | ||
| Half Life | ~288 hrs | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Alemtuzumab.html | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00109 | ||
| CAS Registry Number | Not Available | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:533268 | ||
| PharmGKB ID | PA10010 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |